T Cell News and Research

Latest T Cell News and Research

Chaperone protein study could lead to effective therapies for Alzheimer's, neurological disorders

Dynamic regulation of the chaperone protein Hsp27 was required to get rid of abnormally accumulating tau in the brains of mice genetically modified to develop the memory-choking tau tangles associated with Alzheimer's disease, a University of South Florida-led study found.

4 Dec 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova Therapeutics announces its late-stage anticancer agent, Estybon- (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

4 Dec 2010

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Ligand Pharmaceuticals Incorporated today announced that multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4-7, 2010.

4 Dec 2010

EHSI announces acquisition of Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. announced today that it has acquired a Rotary Cell Culture System, or bioreactor, developed using revolutionary NASA research in the field of microgravity.

4 Dec 2010

New clues into mechanisms underlying antiphospholipid syndrome

Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.

4 Dec 2010

Electronic cigarettes are potentially harmful, researchers say

Electronic cigarettes (or e-cigarettes), also called "electronic nicotine delivery systems," are increasingly used worldwide even though only sparse information is available on their health effects. In the United States, e-cigarettes are readily available in shopping malls in most states and on the Internet.

4 Dec 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

Key findings on plasma cell disorders to be presented at American Society of Hematology Annual Meeting

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced that Dr. Raul Braylan, Hematopathologist and Clinical Medical Director of Hematopathology Services, will present key findings related to plasma cell disorders at the upcoming 52nd Annual Meeting and Exposition of the American Society of Hematology.

4 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Scripps scientists find way to transform mature human cells into stem cells

Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells. The ability to transform fully mature adult cells such as skin cells into stem cells has potentially profound implications for treating many diseases.

3 Dec 2010

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

3 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

Arthritis drug reduces incidence of non-melanoma skin cancers

A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.

3 Dec 2010

Sagent launches chemotherapy agent topotecan hydrochloride for injection

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA approval and launch of its topotecan hydrochloride for injection, a chemotherapy agent, in conjunction with the innovator's patent expiry. Sagent's topotecan is available in 4 mg single-dose latex-free vials.

3 Dec 2010

Research on ribosome could aid antibiotic development against MRSA infection

Theoretical biologists at Los Alamos National Laboratory have used a New Mexico supercomputer to aid an international research team in untangling another mystery related to ribosomes-those enigmatic jumbles of molecules that are the protein factories of living cells.

3 Dec 2010

Advanced Cell Technology eliminates $3 million in debt, strengthens balance sheet

Advanced Cell Technology, Inc. announced today that it has strengthened its balance sheet through the elimination of approximately $3 million in debt over the past several weeks. The conversion of senior and subordinated debentures to equity has reduced the Company's outstanding convertible debentures to approximately $890,000. Since September 2009, Advanced Cell has eliminated approximately $33 million in indebtedness.

3 Dec 2010

Study of proteins under jam-packed conditions may open new treatment for diseases

People in a jetliner act and feel one way when crammed together like sardines in a can. But they have quite a different mindset when the middle seat is empty and they have more personal space. Scientists are pursuing a remarkable parallel that exists among the proteins involved in health and disease inside living cells.

3 Dec 2010

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

Arteriocyte launches Stem Cell Expansion System for research use

Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.

2 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

T Cell News and Research

Latest T Cell News and Research

Chaperone protein study could lead to effective therapies for Alzheimer's, neurological disorders

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

EHSI announces acquisition of Rotary Cell Culture System

New clues into mechanisms underlying antiphospholipid syndrome

Electronic cigarettes are potentially harmful, researchers say

Research findings could provide breakthrough for development of effective therapies for NSCLC

Key findings on plasma cell disorders to be presented at American Society of Hematology Annual Meeting

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Scripps scientists find way to transform mature human cells into stem cells

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

Arthritis drug reduces incidence of non-melanoma skin cancers

Sagent launches chemotherapy agent topotecan hydrochloride for injection

Research on ribosome could aid antibiotic development against MRSA infection

Advanced Cell Technology eliminates $3 million in debt, strengthens balance sheet

Study of proteins under jam-packed conditions may open new treatment for diseases

SAGE launches two new journals in Drug Safety, Hematology

Arteriocyte launches Stem Cell Expansion System for research use

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in